Current Science

Open Access Open Access  Restricted Access Subscription Access

Potent Antitumour Activity of (-)Epigallocatechin Gallate: Indications from In Vitro, In Vivo and in Silico Studies


Affiliations
1 Department of Biotechnology, Center for Post-Graduate Studies, Jain University, Bengaluru 560 011, India
2 Department of Biology, Syngene International Limited, Jigani Link Road, Bengaluru 560 011, India
3 Institute of Molecular and Cell Biology, Biopolis, Singapore
 

Antitumour efficacy of (-)epigallocatechin-3-gallate (EGCG) was evaluated in vitro against the cancer cell lines BxPC-3 (pancreatic cancer), A549 (lung cancer), SH-SY5Y (neuroblastoma), MDA-MB-231 and MCF-7 (breast cancer); in vivo in nude mice by tumour growth inhibition of pancreatic cancers (BxPC-3, MIAPaCa-2), breast cancer (MDA-MB-231), and in silico by docking studies. EGCG significantly inhibited these cancer cell lines in vitro and showed significant tumour reduction in vivo. EGCG docked on to the Her-2 receptor (1N8Y) and the tubulin dimer receptor at a site other than the existing docetaxel ligand. Overall our results suggest that EGCG has potent antineoplastic activity.

Keywords

Antitumour Efficacy, Breast Cancer, Docking, Epigallocatechin Gallate, Lung Cancer.
User
Notifications
Font Size


  • Potent Antitumour Activity of (-)Epigallocatechin Gallate: Indications from In Vitro, In Vivo and in Silico Studies

Abstract Views: 526  |  PDF Views: 187

Authors

Samarendra Narayanan
Department of Biotechnology, Center for Post-Graduate Studies, Jain University, Bengaluru 560 011, India
Balaji Ramchandran
Department of Biology, Syngene International Limited, Jigani Link Road, Bengaluru 560 011, India
Satheesh Rajendiran
Department of Biology, Syngene International Limited, Jigani Link Road, Bengaluru 560 011, India
Sarbani Chandra
Department of Biology, Syngene International Limited, Jigani Link Road, Bengaluru 560 011, India
Atul Tiwari
Department of Biology, Syngene International Limited, Jigani Link Road, Bengaluru 560 011, India
Ravisankar Rajarethinam
Institute of Molecular and Cell Biology, Biopolis, Singapore
Ramesh Kureeckal Vasudev
Department of Biotechnology, Center for Post-Graduate Studies, Jain University, Bengaluru 560 011, India

Abstract


Antitumour efficacy of (-)epigallocatechin-3-gallate (EGCG) was evaluated in vitro against the cancer cell lines BxPC-3 (pancreatic cancer), A549 (lung cancer), SH-SY5Y (neuroblastoma), MDA-MB-231 and MCF-7 (breast cancer); in vivo in nude mice by tumour growth inhibition of pancreatic cancers (BxPC-3, MIAPaCa-2), breast cancer (MDA-MB-231), and in silico by docking studies. EGCG significantly inhibited these cancer cell lines in vitro and showed significant tumour reduction in vivo. EGCG docked on to the Her-2 receptor (1N8Y) and the tubulin dimer receptor at a site other than the existing docetaxel ligand. Overall our results suggest that EGCG has potent antineoplastic activity.

Keywords


Antitumour Efficacy, Breast Cancer, Docking, Epigallocatechin Gallate, Lung Cancer.

References





DOI: https://doi.org/10.18520/cs%2Fv110%2Fi2%2F187-195